However, nonselective class I/II pan HDACi reveals profound anti-myeloma efficacy, whereas its clinical utility is limited because of unfavorable toxicities due to the inhibition of the broad range of HDAC isoforms (31, 51). Here, HDAC9 is linked to plasma cell myeloma.